Kimball Electronics (KE) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
18 May, 2026Company overview and strategic positioning
Global provider of electronics manufacturing and contract manufacturing services, specializing in high-complexity, regulated industries such as automotive, medical, and industrial markets.
Operates 7 manufacturing locations across North America, Europe, and Asia, with over 5,500 employees and $1.49B in FY25 revenue.
Portfolio rationalization included divesting non-core businesses and integrating medical CMO into core EMS, improving utilization and focus.
Emphasizes long-term customer partnerships, with 77% of FY25 revenue from customers with relationships over 10 years.
Culture centers on customer focus, people, environmental citizenship, and profit as a measure of efficiency.
Operational capabilities and market focus
Offers integrated services across the product lifecycle: design, prototyping, NPI/TOW, manufacturing, testing, and aftermarket support.
Specializes in advanced engineering, regulatory compliance (FDA, ISO 9001, ISO 13485), and scientific injection molding for medical devices.
Diversified revenue: 49% automotive, 27% medical, 24% industrial in FY25.
Automotive growth driven by vehicle electrification and electronic content; medical focus on Class II/III devices and drug delivery; industrial growth in automation and clean energy.
Financial performance and outlook
Strong balance sheet with debt down 49% from peak, positive cash from operations for 9 consecutive quarters, and $358.5M in short-term liquidity as of March 2026.
Affirmed FY26 guidance: net sales $1.40–$1.46B, adjusted operating income 4.2–4.5% of sales, capex $50–$60M (majority for new Indianapolis facility).
Margin expansion expected from better capacity utilization and increased medical business share.
Capital allocation prioritizes growth investments, especially in medical CMO, with ongoing share repurchases and potential tuck-in M&A.
Latest events from Kimball Electronics
- Q4 growth and margin gains set up a 7–9% FY27 outlook, driven by medical and Helvoet.KE
Q4 2026 - Medical segment growth and new facility drive raised outlook and margin expansion plans.KE
2026 KeyBanc Capital Markets Healthcare Forum - Acquisition expands global medical CMO platform, boosting growth and earnings by 2027.KE
M&A announcement - Medical-led sequential growth and strong margins support high-end fiscal 2026 outlook.KE
Q3 2026 - Raised FY26 guidance and expanded medical focus drive profitable growth outlook.KE
Company presentation - Q2 sales fell 5% but margins and 2026 guidance improved on strong medical growth.KE
Q2 2026 - Q1 FY2025 sales fell 15% as restructuring and asset sales improved cash flow and reduced debt.KE
Q1 2025 - Q4 sales dropped 13% as inventory and liquidity improved; 2025 outlook remains cautious.KE
Q4 2024 - Streamlined operations and global focus drive resilience despite EMS market headwinds.KE
The Stifel 2024 Cross Sector Insight Conference